Tiziana Life Sciences Announces An Interview on Clinical Improvements for 2nd SPMS Patient
June 09 2022 - 12:25PM
Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"),
a biotechnology company enabling breakthrough immunotherapies via
novel routes of drug administration, today announces an interview
with Chief Executive Officer and Chief Scientific Officer Kunwar
Shailubhai, PhD and Proactive Investors discussing the positive
clinical results from the second patient with Secondary Progressive
Multiple Sclerosis (SPMS) in the ongoing study as part of an
expanded access program at the Brigham and Women’s Hospital (BWH),
Boston, MA.
About Foralumab Foralumab (formerly NI-0401),
the only entirely human anti-CD3 mAb, shows reduced release of
cytokines after IV administration in healthy volunteers and in
patients with Crohn's disease. In a humanized mouse model (NOD/SCID
IL2γc-/-), it was shown that while targeting the T-cell receptor,
orally administered foralumab modulates immune responses of the
T-cells and enhances regulatory T-cells (Tregs), thereby providing
therapeutic benefit in treating inflammatory and autoimmune
diseases without the occurrence of potential adverse events usually
associated with parenteral mAb therapy. Once a day treatment for 10
consecutive days with intranasal foralumab was not only well
tolerated but it also produced strong clinical responses in
COVID-19 patients. Based on these studies, the intranasal and oral
administration of foralumab offers the potential to become a
well-tolerated immunotherapy for autoimmune and inflammatory
diseases by the induction of Tregs.
About Tiziana Life SciencesTiziana Life
Sciences is a clinical-stage biopharmaceutical company developing
breakthrough therapies using transformational drug delivery
technologies to enable alternative routes of immunotherapy.
Tiziana's innovative nasal, oral and inhalation approaches in
development have the potential to provide an improvement in
efficacy as well as safety and tolerability compared to intravenous
(IV) delivery. Tiziana's two lead candidates, intranasal foralumab,
the only fully human anti-CD3 mAb, and milciclib, a pan-CDK
inhibitor, have both demonstrated a favorable safety profile and
clinical response in patients in studies to date. Tiziana's
technology for alternative routes of immunotherapy has been
patented with several applications pending and is expected to allow
for broad pipeline applications.Forward-Looking
StatementsCertain statements made in this announcement are
forward-looking statements. These forward-looking statements are
not historical facts but rather are based on the Company's current
expectations, estimates, and projections about its industry; its
beliefs; and assumptions. Words such as 'anticipates,' 'expects,'
'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar
expressions are intended to identify forward-looking statements.
These statements are not guarantees of future performance and are
subject to known and unknown risks, uncertainties, and other
factors, some of which are beyond the Company's control, are
difficult to predict, and could cause actual results to differ
materially from those expressed or forecasted in the
forward-looking statements. The Company cautions security holders
and prospective security holders not to place undue reliance on
these forward-looking statements, which reflect the view of the
Company only as of the date of this announcement. The
forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company
will not undertake any obligation to release publicly any revisions
or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
For further inquiries:
Tiziana Life Sciences
LtdHana Malik, Business Development, and Investor
Relations Manager +44 (0) 207 495
2379email: info@tizianalifesciences.com |
|
A video accompanying this announcement is available
at https://www.globenewswire.com/NewsRoom/AttachmentNg/459a0c78-4160-4592-b971-84ee0ff0ea53
Tiziana Life Sciences (NASDAQ:TLSA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tiziana Life Sciences (NASDAQ:TLSA)
Historical Stock Chart
From Jul 2023 to Jul 2024